Generic Name: ixazomib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Takeda

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

General Info

Ninlaro is a proteasome inhibitor that targets an enzyme that digests and eliminates excess proteins in myeloma cells. Blocking proteasome activity leads to myeloma cell death.

Clinical trials showed that Ninlaro in combination with other medications slows progression of multiple myeloma.


Dosing Info:

Ninlaro is a pill taken on days 1, 8 and 15 in a monthly cycle. It should be taken at least one hour before or at least two hours after food.

Side Effects

Common side effects include diarrhea, constipation, nausea, peripheral neuropathy, swelling, back pain and depletion of platelets (thrombocytopenia), which can lead to easy bleeding. It can cause birth defects and should not be used during pregnancy.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 18, 2018